搜索

Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS

Why Choose Us?

Bringing global vaccine innovations to China, and delivering China's premium vaccines to the world.

quanfu quanfu

Corporate Strength

Ab&B Bio-Tech Co., Ltd. (JS) has a registered capital of 360 million yuan, with a total land area of 173 acres and a total construction area of 228,000 square meters. The No. 1 Production Park covers 69 acres, with a building area of 80,000 square meters and an investment of 1 billion yuan; the No. 2 Production Park covers 72 acres, with a building area of 120,000 square meters and an investment of 2 billion yuan; and the No. 3 Production Park covers 32 acres, with a building area of 28,000 square meters and an investment of 600 million yuan.

quanfu quanfu

Products & Services

We are committed to the full-cycle development of innovative human vaccines - from research and development through registration, industrial production to commercialization - while adhering to international standards and maintaining our focus on independent innovation.

quanfu quanfu

Scientific Research Capability

Our Shanghai and Taizhou R&D Centers with pilot-scale platforms are actively developing multiple vaccine pipelines including viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccines.

Product Pipelines

At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.

Listed products

Listed products

The Quadrivalent Subunit Influenza Vaccine is developed using the company's own patented technology and is in phase III clinical trial. It has the characteristics of high purity and good safety, especially suitable for children. Currently, no such products are available on the market at home and abroad.

More Product Series

Products under development

Products under development

This product uses the truncated VZV gE protein with independent intellectual property rights of our company as the antigen, and contains major B-cell and T-cell epitopes. Equipped with the self-developed dual adjuvant system, it can induce the body to produce strong specific humoral and cellular immune responses. All adjuvants used have been applied in marketed vaccines.

More Product Series

News Center

The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
2025-02-18

Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
→

Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
2024-12-30

Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
→

Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held
2024-12-25

Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by the Guangzhou Women and Children's Medical Center as the lead research unit, aiming to provide evidence-based influenza vaccination guidelines for children with nephrotic syndrome as a special population, thereby reducing their risk of influenza virus infection and severe complications.
→

Got a project? Contact us today !

At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.

Contact

E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search